At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Nov 6, 2026 at 16:03 ET
Two Teva insiders sold shares in the open market days after the company reported a Q3 2026 earnings beat and raised guidance. The combined $2.29M in sales is modest relative to Teva's market cap, but the timing and absence of 10b5-1 plans suggest potential profit-taking after the stock's post-earnings strength.
- Two insiders sold a combined $2.29M in open-market sales on Nov 4-5, 2026
- Sales followed Teva's Q3 2026 earnings beat (non-GAAP EPS $0.86 vs $0.72 consensus) and raised 2026 revenue outlook
- Neither sale was executed under a 10b5-1 plan
- Total sales represent approximately 0.07% of Teva's market cap (estimated ~$3.3B based on ~79M shares at $41.72)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access